Additionally, since the cetuximab and IMC-A12 treatments were limited to only three times at 3-d intervals, differential up-regulation of EGFR or IGF-1R after the termination of treatments may have contributed to accelerated tumor growth. The gene discussed is EGFR; the disease is neoplasm.